Brainsway Ltd ADR Dossier
Qualitative Analysis
Business overview
BrainsWay Ltd. is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The company's flagship technology is its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform. Deep TMS utilizes magnetic pulses to stimulate neurons and modulate physiological activity in deeper and broader areas of the brain than traditional TMS. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies: Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), and smoking addiction. The company operates primarily through a high-margin recurring revenue model, leasing and selling its systems to psychiatrists, hospitals, and medical centers globally.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Acquiring minority positions in leading growth-oriented U.S. mental health provider networks to help them raise awareness, open new clinics, and expand access to Deep TMS therapy.
Expected impact: Accelerates organic growth, adds new clinics, deepens system utilization, and scales high-margin recurring revenue without materially increasing operating expenses.
Shifting the commercial business model from one-time system sales to a high-margin, recurring revenue model anchored in multi-year Deep TMS system leases and pay-per-use agreements.
Expected impact: Reduces upfront costs for clinics to drive faster adoption, resulting in predictable, high-margin annual recurring revenue (ARR) and sustained positive free cash flow.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides BrainsWay with a structured M&A option and entry into the at-home neuromodulation market, complementing its in-clinic Deep TMS technology with Neurolief's wearable Proliv™Rx system.
Terms: BrainsWay has invested $11 million to date, including a $5 million convertible loan in 2025 and a $6 million milestone-based convertible loan completed on March 26, 2026. The agreement provides for a potential third tranche of up to $5 million upon achieving defined revenue targets, and a call option for BrainsWay to acquire all outstanding equity.
Expands access to and awareness of advanced interventional psychiatry solutions, including Deep TMS, across Hopemark's clinical network in the greater Chicago area.
Terms: Initial investment of $1.5 million on May 18, 2026, with potential for an additional $1.5 million via milestone-based investments, in exchange for a minority position in the form of a preferred, annually compounding security with a redemption mechanism.
Supports the expansion of Axis's clinical services platform and new clinic locations in Colorado, driving increased utilization of Deep TMS treatments.
Terms: Initial investment of $2.3 million in August 2025, followed by a completed $1 million milestone-based investment on March 19, 2026, after Axis achieved a predefined revenue performance milestone. Held as a minority preferred, annually compounding security with a redemption mechanism.
Expands BrainsWay's presence and clinical footprint in the North American mental health sector.
Terms: Initial investment of $1 million announced in early 2026, with potential for an additional $1.5 million in milestone-based investments, structured as a preferred, annually compounding security.